Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03901781 · ClinicalTrials.gov registry record · Phase 1
Study of ST266 Given by Intranasal Delivery in Glaucoma Suspect Subjects
A Phase 1 study of Ocular Hypertension, sponsored by Noveome Biotherapeutics, formerly Stemnion.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT03901781: Completed Phase 1 study of Ocular Hypertension, sponsored by Noveome Biotherapeutics, formerly Stemnion.
NCT03901781 is a Phase 1 study of Ocular Hypertension that has completed, run by Noveome Biotherapeutics, formerly Stemnion. The registered enrollment target is 9 participants, below the 278-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03901781, a Phase 1 study of Ocular Hypertension, has completed, sponsored by Noveome Biotherapeutics, formerly Stemnion.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this trial is to assess the safety of ST266 given by non-invasive intranasal trans-cribriform delivery to glaucoma suspect subjects with ocular hypertension, optic nerve cupping, or family history of glaucoma.
Primary Outcome
Safety will be determined by comparing the results of the screening tests at baseline and again at the end of the treatment period through the end of study. Adverse events (AEs) and Serious Adverse Events (SAEs) will be recorded. The primary safety variable is the incidence of subjects with any adverse event during the entire study.
Conditions Studied
Interventions
- COMBINATION_PRODUCT ST266 via Intranasal Delivery
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2019-10-23 |
| Est. Completion | 2022-05-20 |
| Phase | Phase 1 |
What the finished NCT03901781 record still lists
NCT03901781 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 278-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Ocular Hypertension appearing as the primary indexed condition, and to 1 intervention - of which ST266 via Intranasal Delivery is the first listed.
NCT03901781 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03901781 about?
NCT03901781 is a clinical study titled "Study of ST266 Given by Intranasal Delivery in Glaucoma Suspect Subjects". The primary objective of this trial is to assess the safety of ST266 given by non-invasive intranasal trans-cribriform delivery to glaucoma suspect subjects with ocular hypertension, optic nerve cupping, or family history of glaucoma.
What is the current status of trial NCT03901781?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2019-10-23. Estimated completion is 2022-05-20.
What conditions does trial NCT03901781 study?
This clinical trial studies the following conditions: Ocular Hypertension.
What interventions are being tested in trial NCT03901781?
The interventions under investigation include: ST266 via Intranasal Delivery (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03901781?
This trial is sponsored by Noveome Biotherapeutics, formerly Stemnion, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03901781 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03901781's enrollment target sits among peer trials
9 55th of 54 the lowest of 54 other Ocular Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ocular Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
RECRUITING · Phase 1
-
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 1
-
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
ACTIVE NOT RECRUITING · Phase 1
-
Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution
ACTIVE NOT RECRUITING · Phase 1
-
Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma
COMPLETED · Phase 1
-
A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI